Drug Profile
Research programme: tyrosine kinase inhibitors - EyePoint Pharmaceuticals
Alternative Names: Durasert™ TKI insertLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator pSivida
- Developer EyePoint Pharmaceuticals
- Class Eye disorder therapies
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Wet age-related macular degeneration
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Topical, Controlled release)
- 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
- 07 Feb 2017 Research programme: tyrosine kinase inhibitors - pSivida is available for licensing as of 07 Feb 2017. http://www.psivida.com